Role of Allogeneic Stem Cell Transplantation in Current Treatment of Acute Myeloid Leukemia

Jan J. Cornelissen, Bob Löwenberg

doi:10.1182/asheducation-2005.1.151

Role of Allogeneic Stem Cell Transplantation in Current Treatment of Acute Myeloid Leukemia

DOI PDF 被引用文献3件

説明

<jats:title>Abstract</jats:title> <jats:p>Allogeneic hematopoietic stem cell transplantation (alloSCT) has been established as an effective consolidation therapy in acute myeloid leukemia (AML) in first or subsequent remission. Although it effectively prevents relapse, treatment-related mortality (TRM) associated with alloSCT may compromise that beneficial effect. As a result, alloSCT may be restricted to patients with a relatively high risk of relapse. Here, we review studies that identify categories of AML patients who may specifically benefit from alloSCT. In addition, we discuss recent developments with respect to alternative donors, stem cell sources, and supportive care. Finally, we highlight recent results obtained with reduced-intensity alloSCT, which already significantly influence our therapeutic strategy in elderly patients with AML.</jats:p>